

# Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

New England Journal of Medicine

384, 705-716

DOI: [10.1056/nejmoa2024850](https://doi.org/10.1056/nejmoa2024850)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Immune Therapies for Myeloma: The CARs Are Here but What's Next?. , 2021, 18, .		0
2	Cancer Immunology. , 2021, , .		0
3	Antibodies Against Vaccine-preventable Infections After CD19 or BCMA CAR T-cell Therapy. , 2021, 18, .		0
4	IFN Signaling and Myeloid Cells in the Setting of CAR T: A Central Role for the Induction of Endogenous Anti-tumor Immunity. , 2021, 18, .		0
5	Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Annals of Medicine, 2021, 53, 1547-1559.	1.5	15
6	Adoptive Cellular Therapy for Solid Tumors. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 57-65.	1.8	10
7	A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma. OncoTargets and Therapy, 2021, Volume 14, 2185-2201.	1.0	9
8	How to Treat High-Risk Myeloma at Diagnosis and Relapse. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, 291-309.	1.8	27
9	A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma. Expert Review of Hematology, 2021, 14, 377-389.	1.0	6
10	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 2021, 13, 1781.	1.7	17
11	Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 302-318.	2.6	40
12	Chimeric Antigen Receptorâ€“Modified T Cells and T Cellâ€“Engaging Bispecific Antibodies: Different Tools for the Same Job. Current Hematologic Malignancy Reports, 2021, 16, 218-233.	1.2	4
13	Reactions Related to CAR-T Cell Therapy. Frontiers in Immunology, 2021, 12, 663201.	2.2	54
14	Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. Journal of Hematology and Oncology, 2021, 14, 66.	6.9	35
15	CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer Journal, 2021, 11, 84.	2.8	97
16	Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma. Cancers, 2021, 13, 1686.	1.7	25
17	Future Directions in Maintenance Therapy in Multiple Myeloma. Journal of Clinical Medicine, 2021, 10, 2261.	1.0	8
19	Current and Novel Alkylators in Multiple Myeloma. Cancers, 2021, 13, 2465.	1.7	12

#	ARTICLE	IF	CITATIONS
20	Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma. Cancer Journal (Sudbury, Mass ), 2021, 27, 205-212.	1.0	1
21	Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and reviews of the literature. Cancer Immunology, Immunotherapy, 2022, 71, 39-44.	2.0	18
23	Context matters in CAR T cell tonic signaling. Nature Medicine, 2021, 27, 763-764.	15.2	4
24	How Can We Engineer CAR T Cells to Overcome Resistance?. Biologics: Targets and Therapy, 2021, Volume 15, 175-198.	3.0	8
25	Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health. JCO Clinical Cancer Informatics, 2021, 5, 668-678.	1.0	20
26	Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 741-751.	0.2	5
27	Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies. Current Medical Science, 2021, 41, 420-430.	0.7	5
28	Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments. Current Hematologic Malignancy Reports, 2021, 16, 345-356.	1.2	21
29	InÂvivo targeting of lentiviral vectors pseudotyped with the Tupaia paramyxovirus H glycoprotein bearing a cell-specific ligand. Molecular Therapy - Methods and Clinical Development, 2021, 21, 670-680.	1.8	2
30	CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e246-e265.	1.8	27
31	Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients. Journal of Translational Medicine, 2021, 19, 265.	1.8	20
32	KarMMa-RW: comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma. Blood Cancer Journal, 2021, 11, 116.	2.8	44
33	Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety. Drug Design, Development and Therapy, 2021, Volume 15, 2401-2415.	2.0	26
34	Finding the Optimal Partner to Pair with Bispecific Antibody Therapy for Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 297-299.	2.6	3
35	New targets for CAR T therapy in hematologic malignancies. Best Practice and Research in Clinical Haematology, 2021, 34, 101277.	0.7	9
36	CAR T-Cell Therapy: Updates in Nursing Management. Clinical Journal of Oncology Nursing, 2021, 25, 255-258.	0.3	6
37	Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products. Pharmaceutical Research, 2021, 38, 931-945.	1.7	18
38	Clinical experience of CAR T cell therapy in lymphomas. Best Practice and Research in Clinical Haematology, 2021, 34, 101281.	0.7	1

#	ARTICLE	IF	CITATIONS
39	Industry updates from the field of stem cell research and regenerative medicine in February 2021. <i>Regenerative Medicine</i> , 2021, 16, 517-523.	0.8	1
40	Idecabtagene Vicleucel in Relapsed Myeloma. <i>New England Journal of Medicine</i> , 2021, 384, 2356-2358.	13.9	5
41	Toci or not toci: innovations in the diagnosis, prevention, and early management of cytokine release syndrome. <i>Leukemia and Lymphoma</i> , 2021, 62, 2600-2611.	0.6	9
42	Novel strategies for immuno-oncology breakthroughs with cell therapy. <i>Biomarker Research</i> , 2021, 9, 62.	2.8	18
43	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	1.3	11
44	Novel antigens of CAR T cell therapy: New roads; old destination. <i>Translational Oncology</i> , 2021, 14, 101079.	1.7	30
45	Smoldering multiple myeloma – Past, present, and future. <i>Blood Reviews</i> , 2021, , 100869.	2.8	2
46	IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. <i>Cancers</i> , 2021, 13, 3534.	1.7	19
47	The Cancer-Immunity Cycle in Multiple Myeloma. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 247-260.	2.7	11
48	Immunotherapy in Multiple Myeloma – Time for a Second Major Paradigm Shift. <i>JCO Oncology Practice</i> , 2021, 17, 405-413.	1.4	10
49	Selinexor for the treatment of patients with previously treated multiple myeloma. <i>Expert Review of Hematology</i> , 2021, 14, 697-706.	1.0	6
50	A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 715-727.	12.5	136
51	Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 698607.	1.3	25
52	Epidemiology of Amyloidosis and Genetic Pathways to Diagnosis and Typing. <i>Hemato</i> , 2021, 2, 429-440.	0.2	0
53	Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. <i>Biotechnology and Bioengineering</i> , 2021, 118, 3691-3705.	1.7	13
54	Applying State-of-the-Art Survival Extrapolation Techniques to the Evaluation of CAR-T Therapies: Evidence from a Systematic Literature Review. <i>Advances in Therapy</i> , 2021, 38, 4178-4194.	1.3	4
55	Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 558-570.	0.6	36
56	Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3087-3097.	0.6	5

#	ARTICLE	IF	CITATIONS
57	Requirements for operational cure in multiple myeloma. <i>Blood</i> , 2021, 138, 1406-1411.	0.6	10
58	Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 965-973.	1.9	13
59	Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idcabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2021, 37, 1779-1788.	0.9	21
60	Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond. <i>Journal of Hematology and Oncology</i> , 2021, 14, 115.	6.9	13
61	Toxicities associated with adoptive cellular therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101287.	0.7	9
62	Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet, The</i> , 2021, 398, 314-324.	6.3	711
63	Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4019.	1.7	9
64	Clinical experience of CAR T cells for multiple myeloma. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101306.	0.7	8
66	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. <i>International Journal of Cancer</i> , 2021, 149, 1980-1996.	2.3	25
67	Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma. <i>Current Opinion in Immunology</i> , 2021, 71, 117-123.	2.4	4
68	Teclistamab, a B-cell maturation antigen- $\hat{A}$ - $\hat{A}$ CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. <i>Lancet, The</i> , 2021, 398, 665-674.	6.3	138
69	Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). <i>European Journal of Haematology</i> , 2021, 107, 602-608.	1.1	7
70	Idecabtagene vicleucel: questions regarding the appropriate role and cost. <i>British Journal of Haematology</i> , 2022, 196, .	1.2	3
71	Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. <i>Cancer Cell</i> , 2021, 39, 1031-1033.	7.7	219
72	Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. <i>Frontiers in Pharmacology</i> , 2021, 12, 720692.	1.6	20
73	Effective anti-BCMA retreatment in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 3016-3020.	2.5	30
75	Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models. <i>Cancers</i> , 2021, 13, 4301.	1.7	7
77	Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells. <i>Cancer Cell International</i> , 2021, 21, 450.	1.8	11

#	ARTICLE	IF	CITATIONS
78	Targeting BCMA in Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 367-383.	1.2	6
79	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- $\gamma$ and $\beta$ . <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
80	A new era of novel immunotherapies for multiple myeloma. <i>Lancet, The</i> , 2021, 398, 642-643.	6.3	6
81	CAR T cells: Building on the CD19 paradigm. <i>European Journal of Immunology</i> , 2021, 51, 2151-2163.	1.6	43
82	The role of autologous stem-cell transplantation in multiple myeloma in 2021. <i>Current Opinion in Oncology</i> , 2021, 33, 642-647.	1.1	5
83	On the road to eliminating long-lived plasma cells—are we there yet? <i>Immunological Reviews</i> , 2021, 303, 154-167.	2.8	13
84	Engineering the next generation of CAR-NK immunotherapies. <i>International Journal of Hematology</i> , 2021, 114, 554-571.	0.7	37
85	The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond. <i>Cancers</i> , 2021, 13, 4701.	1.7	6
86	Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 6384-6392.	3.2	27
87	The Past, Present, and Future of Economic Evaluations of Precision Medicine at the Committee for Economic Analyses of the Canadian Cancer Trials Group. <i>Current Oncology</i> , 2021, 28, 3649-3658.	0.9	0
88	A randomized phase 2 trial of idiotype vaccination and adoptive autologous T-cell transfer in patients with multiple myeloma. <i>Blood</i> , 2022, 139, 1289-1301.	0.6	9
89	Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy. <i>Cancers</i> , 2021, 13, 4806.	1.7	5
90	Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2045-2054.	2.5	46
91	Immunotherapy of Multiple Myeloma: Promise and Challenges. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 343-371.	2.7	11
92	The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies. <i>HemaSphere</i> , 2021, 5, e642.	1.2	2
93	Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy. <i>Cancers</i> , 2021, 13, 4785.	1.7	15
94	The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. <i>British Journal of Haematology</i> , 2022, 196, 488-506.	1.2	14
95	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. <i>Blood Advances</i> , 2021, 5, 4465-4475.	2.5	28

#	ARTICLE	IF	CITATIONS
96	Harnessing the Immune System to Fight Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4546.	1.7	10
98	Extracellular Vesicles Derived from Chimeric Antigen Receptor-T Cells: A Potential Therapy for Cancer. <i>Human Gene Therapy</i> , 2021, 32, 1224-1241.	1.4	24
99	Advances in mRNA-based drug discovery in cancer immunotherapy. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 41-53.	2.5	17
100	State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 973-987.	0.6	25
101	Tagging and Capturing of Lentiviral Vectors Using Short RNAs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10263.	1.8	0
102	Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma. , 2022, 232, 108007.		12
103	Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pretreated relapsed and refractory multiple myeloma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1315-1320.	0.5	3
104	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	6.6	8
105	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
106	BCMA-Directed CAR T-Cells: Early Results and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S162-S165.	0.2	0
107	Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 407-421.	1.4	1
108	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 807-816.	0.6	3
109	Rethinking mechanisms of neurotoxicity with BCMA directed therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 166, 103453.	2.0	6
110	Genome editing in large animal models. <i>Molecular Therapy</i> , 2021, 29, 3140-3152.	3.7	18
111	Roadmap to cure multiple myeloma. <i>Cancer Treatment Reviews</i> , 2021, 100, 102284.	3.4	44
112	Gene therapy process change evaluation framework: Transient transfection and stable producer cell line comparison. <i>Biochemical Engineering Journal</i> , 2021, 176, 108202.	1.8	10
113	Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. <i>Oncolmmunology</i> , 2021, 10, 1959102.	2.1	19
114	The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110196.	1.1	8

#	ARTICLE	IF	CITATIONS
115	Infectious complications of CAR T-cell therapy: a clinical update. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110367.	1.1	28
116	An overview of multiplexed analyses of CAR T-cell therapies: insights and potential. <i>Expert Review of Proteomics</i> , 2021, 18, 767-780.	1.3	2
117	A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 161.	6.9	90
118	CRISPR-derived genome editing therapies: Progress from bench to bedside. <i>Molecular Therapy</i> , 2021, 29, 3125-3139.	3.7	14
119	CAR T-cell therapy and critical care. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1318-1325.	1.0	18
120	Advances in immune therapies in hematological malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 205-220.	2.7	5
121	Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma. <i>Cancers</i> , 2021, 13, 4978.	1.7	6
122	Current State of the Art and Prospects of T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2021, 10, 4593.	1.0	11
123	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. <i>Cancers</i> , 2021, 13, 5154.	1.7	30
124	An Allogeneic Multiple Myeloma GM-CSF-“Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. <i>Clinical Cancer Research</i> , 2021, 27, 6696-6708.	3.2	8
125	Promise and pitfalls of allogeneic chimeric antigen receptor therapy in plasma cell and lymphoid malignancies. <i>British Journal of Haematology</i> , 2022, 197, 28-40.	1.2	9
126	From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives. <i>Cells</i> , 2021, 10, 2845.	1.8	6
127	Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update. <i>American Journal of Hematology</i> , 2022, 97, 99-118.	2.0	23
128	Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond. <i>Cancers</i> , 2021, 13, 5036.	1.7	11
129	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1800-1813.	1.2	55
130	Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. <i>Frontiers in Immunology</i> , 2021, 12, 755866.	2.2	18
131	Process analytical technologies in cell therapy manufacturing: State-of-the-art and future directions. <i>Journal of Advanced Manufacturing and Processing</i> , 2022, 4, .	1.4	16
132	Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 326-335.	0.2	27



#	ARTICLE	IF	CITATIONS
133	Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 1255-1263.	2.5	26
134	Generation of an NF $\kappa$ B-Driven Alpharetroviral "All-in-One" Vector Construct as a Potent Tool for CAR NK Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 751138.	2.2	11
135	Treatment of multiple myeloma in 2021. <i>Klinicka Farmakologie A Farmacie</i> , 2021, 35, 70-77.	0.1	2
137	The Use of Oncolytic Viruses in the Treatment of Multiple Myeloma. <i>Cancers</i> , 2021, 13, 5687.	1.7	6
138	The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 45-51.	0.5	0
139	Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. <i>Cancers</i> , 2021, 13, 5886.	1.7	4
140	CAR-T CELL OPENIA: Chimeric antigen receptor T cell therapy-associated cytopenias. <i>EJHaem</i> , 2022, 3, 32-38.	0.4	16
142	Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. <i>EJHaem</i> , 2022, 3, 6-10.	0.4	63
143	Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. <i>Leukemia</i> , 2022, 36, 877-880.	3.3	18
144	Comparative Efficacy of Ciltacabtagene Autoleucl in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. <i>Clinical Drug Investigation</i> , 2022, 42, 29-41.	1.1	16
145	Associa�o Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients. <i>Hematology, Transfusion and Cell Therapy</i> , 2021, 43, S30-S34.	0.1	1
146	New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
147	Role of bridging therapy during chimeric antigen receptor T cell therapy. <i>EJHaem</i> , 2022, 3, 39-45.	0.4	9
148	T Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy. <i>Frontiers in Immunology</i> , 2021, 12, 780442.	2.2	42
149	Idecabtagene vicleucl (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma. <i>Future Oncology</i> , 2022, 18, 277-289.	1.1	20
150	ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature. <i>Frontiers in Medicine</i> , 2021, 8, 713047.	1.2	3
151	CAR T Cells. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 297-317.	0.8	4
152	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	0.8	2

#	ARTICLE	IF	CITATIONS
154	High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 2.	3.5	28
155	Jahrestagung der American Society of Hematology: Neue Optionen bei Rezidiven. , 0, , .		0
156	CAR-T-Zelltherapie: Konzept "One and Done". , 0, , .		0
159	CAR-T cell: Toxicities issues: Mechanisms and clinical management. Bulletin Du Cancer, 2021, 108, S117-S127.	0.6	7
160	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 8-19.	2.3	80
161	A nano-innate immune system activator for cancer therapy in a 4T1 tumor-bearing mouse model. Journal of Nanobiotechnology, 2022, 20, 54.	4.2	4
162	Advances and perspective of the immunotherapy for relapsed/refractory multiple myeloma (interview). Oncogematologiya, 2022, 17, 43-52.	0.1	1
163	Immunotherapeutic Strategies in Cancer and Atherosclerosis"Two Sides of the Same Coin. Frontiers in Cardiovascular Medicine, 2021, 8, 812702.	1.1	2
164	Chimeric Antigen Receptor T-Cell Therapy in Paediatric B-Cell Precursor Acute Lymphoblastic Leukaemia: Curative Treatment Option or Bridge to Transplant?. Frontiers in Pediatrics, 2021, 9, 784024.	0.9	13
166	Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia. Cancers, 2022, 14, 497.	1.7	17
167	Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners. Biomedicines, 2022, 10, 307.	1.4	9
169	BCMA-Directed CAR T Cells in Relapsed Refractory Multiple Myeloma: Highlights From SOHO 2021. Journal of the Advanced Practitioner in Oncology, 2022, 13, 23-25.	0.2	0
171	The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity. Cancers, 2022, 14, 299.	1.7	11
172	The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies. Biomarker Research, 2022, 10, 1.	2.8	22
174	Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells. International Journal of Molecular Sciences, 2022, 23, 903.	1.8	7
175	How I treat relapsed multiple myeloma. Blood, 2022, 139, 2904-2917.	0.6	16
176	The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma. Journal of Oncology Pharmacy Practice, 2022, 28, 960-968.	0.5	6
177	Equitable access to cell and gene therapies in South Africa: opportunities and hurdles. Gene Therapy, 2023, 30, 180-186.	2.3	8

#	ARTICLE	IF	CITATIONS
178	Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. <i>Cells</i> , 2022, 11, 410.	1.8	9
179	Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 77-85.	0.2	10
180	Current state and next-generation CAR-T cells in multiple myeloma. <i>Blood Reviews</i> , 2022, 54, 100929.	2.8	38
181	Manufacturing of CAR-T Cells: The Assembly Line. <i>Cancer Drug Discovery and Development</i> , 2022, , 121-139.	0.2	1
183	â€œSave the day with a Stem Cell Rescueâ€™™: Use of autologous hematopoietic stem cell boost for hematopoietic recovery after CAR T cell therapy. <i>Bone Marrow Transplantation</i> , 2022, 57, 504-506.	1.3	5
184	DUPLICATE: Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	0
185	Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 460-473.	0.2	13
186	The next wave of cellular immunotherapies in pancreatic cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 561-576.	2.0	34
187	Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions. <i>Oncology and Therapy</i> , 2022, , 1.	1.0	0
188	Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy. <i>EJHaem</i> , 2022, 3, 533-536.	0.4	2
189	Melflufen for multiple myeloma: a promise unfulfilled?. <i>Lancet Haematology,the</i> , 2022, 9, e82-e84.	2.2	8
190	Diagnosis and Management of Multiple Myeloma. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 464.	3.8	308
191	<scp>Realâ€world</scp> applicability of commercial chimeric antigen receptor Tâ€cell therapy among older adults with relapsed and/or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	6
192	A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy. <i>Frontiers in Pharmacology</i> , 2022, 13, 803693.	1.6	6
194	Post-CAR-T Cell Therapy (Consolidation and Relapse): Multiple Myeloma. , 2022, , 173-176.		1
196	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models. <i>Methods in Cell Biology</i> , 2022, 167, 185-201.	0.5	0
197	Pharmacological Aspects of Clinically Approved Gene Therapy Drugs and Products. , 2022, , .		0
198	Tumour Escape from CAR-T Cells. , 2022, , 15-22.		4

#	ARTICLE	IF	CITATIONS
199	Novel systemic treatment approaches for metastatic pancreatic cancer. Expert Opinion on Investigational Drugs, 2022, 31, 249-262.	1.9	12
200	Challenges of chimeric antigen receptor T-cell therapy in chronic lymphocytic leukemia: lessons learned. Experimental Hematology, 2022, 108, 1-7.	0.2	9
201	Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine. Diagnostics, 2022, 12, 409.	1.3	5
202	Future Developments in the Treatment of AL Amyloidosis. Hemato, 2022, 3, 131-152.	0.2	2
203	Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Annals of Oncology, 2022, 33, 259-275.	0.6	139
204	Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells. Journal of Controlled Release, 2022, 343, 379-391.	4.8	12
205	Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nature Medicine, 2021, 27, 2099-2103.	15.2	92
206	Modified T cells as therapeutic agents. Hematology American Society of Hematology Education Program, 2021, 2021, 296-302.	0.9	3
207	A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021. Translational Cancer Research, 2022, 11, 772-783.	0.4	2
208	Adoptive T-cell Immunotherapy: Perfecting Self-Defenses. Experientia Supplementum (2012), 2022, 113, 253-294.	0.5	1
209	A Phase I Study of C-CAR088, a Novel Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma. SSRN Electronic Journal, 0, , .	0.4	0
210	Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy. European Journal of Inflammation, 2022, 20, 1721727X2210787.	0.2	0
211	An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment. Therapeutic Advances in Hematology, 2022, 13, 204062072210884.	1.1	2
212	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. Science Translational Medicine, 2022, 14, eaax7706.	5.8	10
213	CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience. , 2022, 10, e004128.		18
214	Targeting of the alpha<sub>v</sub> beta<sub>3</sub> integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma. , 2022, 10, e003816.		24
215	Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma. Blood Advances, 2022, 6, 1309-1318.	2.5	31
216	Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials. Cancer Immunology, Immunotherapy, 2022, , 1.	2.0	5

#	ARTICLE	IF	CITATIONS
217	Advances and Personalized Approaches in the Frontline Treatment of T-Cell Lymphomas. <i>Journal of Personalized Medicine</i> , 2022, 12, 267.	1.1	4
219	Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. <i>Blood Cancer Journal</i> , 2022, 12, 32.	2.8	73
220	Immunotherapy in Advanced Prostate Cancer—Light at the End of the Tunnel?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2569.	1.8	11
221	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	1.8	21
222	Cytopenia after CAR-T Cell Therapy—A Brief Review of a Complex Problem. <i>Cancers</i> , 2022, 14, 1501.	1.7	43
223	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	0.7	8
224	New and emerging pharmacotherapies for management of multiple myeloma. <i>American Journal of Health-System Pharmacy</i> , 2022, , .	0.5	1
225	Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma. <i>Antibodies</i> , 2022, 11, 22.	1.2	1
226	Promising therapeutic approaches for relapsed/refractory multiple myeloma. <i>Hematology</i> , 2022, 27, 343-352.	0.7	4
227	Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma. <i>Haematologica</i> , 2022, 107, 2395-2407.	1.7	7
228	CAR T cell therapy for multiple myeloma: What have we learned?. <i>Leukemia</i> , 2022, 36, 1481-1484.	3.3	3
229	Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy. <i>Exploration</i> , 2022, 2, .	5.4	68
230	Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. <i>Molecular Cancer</i> , 2022, 21, 78.	7.9	88
231	Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2246-2256.	0.8	43
232	Belantamab mafodotin for relapsed or refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210862.	0.5	0
233	Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 294-302.	0.6	17
234	Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. <i>Seminars in Cancer Biology</i> , 2022, 86, 607-623.	4.3	10
235	Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies. <i>European Heart Journal</i> , 2022, 43, 1928-1940.	1.0	39

#	ARTICLE	IF	CITATIONS
236	Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 304.e1-304.e9.	0.6	12
237	Genetic Modification of T Cells for the Immunotherapy of Cancer. <i>Vaccines</i> , 2022, 10, 457.	2.1	2
238	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	2.8	57
239	<i>In Vivo</i> Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 81-89.	2.3	14
240	Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting. <i>Frontiers in Immunology</i> , 2022, 13, 839097.	2.2	4
241	sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1463-1471.	1.0	14
242	Recent Advances in CAR T-Cell Therapy for Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 1715.	1.7	9
243	Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2022, 14, 1677.	1.7	7
244	CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 119.	3.5	167
245	A decade of CAR T cell evolution. <i>Nature Cancer</i> , 2022, 3, 270-271.	5.7	12
246	Monitoring of Circulating CAR T Cells: Validation of a Flow Cytometric Assay, Cellular Kinetics, and Phenotype Analysis Following Tisagenlecleucel. <i>Frontiers in Immunology</i> , 2022, 13, 830773.	2.2	21
247	A genome-scale screen for synthetic drivers of T cell proliferation. <i>Nature</i> , 2022, 603, 728-735.	13.7	84
248	Donor T cells for CAR T cell therapy. <i>Biomarker Research</i> , 2022, 10, 14.	2.8	9
249	How I treat <i>triple</i> refractory multiple myeloma. <i>British Journal of Haematology</i> , 2022, 198, 244-256.	1.2	9
250	Current Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Oncology and Therapy</i> , 2022, 10, 105-122.	1.0	2
251	Change in Neurocognitive Performance Among Patients with Non-Hodgkin Lymphoma in the First Year after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 305.e1-305.e9.	0.6	14
252	Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms. <i>Leukemia and Lymphoma</i> , 2022, 63, 1849-1860.	0.6	14
253	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	1.0	25

#	ARTICLE	IF	CITATIONS
254	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 387-405.	2.3	124
255	CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities. Molecular Therapy - Oncolytics, 2022, 25, 69-77.	2.0	60
256	Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Journal of Experimental and Clinical Cancer Research, 2021, 40, 367.	3.5	72
258	Real-life data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience. Blood Cancer Journal, 2021, 11, 196.	2.8	28
259	Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing. Cells, 2022, 11, 21.	1.8	16
260	New milestones for IOTTECH in 2022. Immuno-Oncology Technology, 2021, 12, 100060.	0.2	0
261	CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies. Frontiers of Medicine, 2021, 15, 783-804.	1.5	3
262	Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances, 2022, 6, 2466-2470.	2.5	29
263	Myeloid Immune Cells CARrying a New Weapon Against Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 784421.	1.8	4
264	High-risk multiple myeloma: how to treat at diagnosis and relapse?. Hematology American Society of Hematology Education Program, 2021, 2021, 30-36.	0.9	15
265	Pepaxto: A New Peptide-Drug Conjugate for Heavily Pretreated Relapsed and Refractory Multiple Myeloma. Annals of Pharmacotherapy, 2022, 56, 951-957.	0.9	5
266	Cancer-Homing CAR-T Cells and Endogenous Immune Population Dynamics. International Journal of Molecular Sciences, 2022, 23, 405.	1.8	11
267	NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Cells, 2021, 10, 3390.	1.8	17
268	Wilms tumor 1 (WT1)–anti-CD19 CAR T cells for relapsed and refractory multiple myeloma. Chinese Science Bulletin, 2022, ,		
269	A TCR mimic CAR T cell specific for NDC80 is broadly reactive with solid tumors and hematologic malignancies. Blood, 2022, 140, 861-874.	0.6	10
270	Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 358-364.	0.6	40
271	Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor T Cell Therapy for Hematological Malignant Neoplasms. JAMA Network Open, 2022, 5, e228161.	2.8	22
272	Haematology laboratory parameters to assess efficacy of CD19, CD22, CD33, and CD123 directed chimeric antigen receptor therapy in haematological malignancies. International Journal of Laboratory Hematology, 2022, ...	0.7	1

#	ARTICLE	IF	CITATIONS
273	CAR T-Cell Therapy in the Older Person: Indications and Risks. <i>Current Oncology Reports</i> , 2022, 24, 1189-1199.	1.8	11
274	Development of CAR T Cell Therapy in Children—A Comprehensive Overview. <i>Journal of Clinical Medicine</i> , 2022, 11, 2158.	1.0	12
275	A novel BCMA CAR-T-cell therapy with optimized human scFv for treatment of relapsed/refractory multiple myeloma: results from phase I clinical trials. <i>Haematologica</i> , 2022, , .	1.7	3
276	T-cell—redirecting bispecific antibodies in multiple myeloma: a revolution?. <i>Blood</i> , 2022, 139, 3681-3687.	0.6	20
277	Small Molecule 20S Proteasome Enhancer Regulates MYC Protein Stability and Exhibits Antitumor Activity in Multiple Myeloma. <i>Biomedicines</i> , 2022, 10, 938.	1.4	5
278	BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. <i>Drugs</i> , 2022, 82, 613-631.	4.9	10
279	Modulating tumor physical microenvironment for fueling CAR-T cell therapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 185, 114301.	6.6	28
280	Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis. <i>Blood Cancer Journal</i> , 2022, 12, 46.	2.8	13
281	Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. <i>Blood Advances</i> , 2023, 7, 768-777.	2.5	15
283	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0
284	New Frontiers: The Role of CAR T-Cell Therapy in Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 328-332.	0.2	1
285	2020—2021 Drug Updates in Hematologic Malignancies. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 282-285.	0.2	0
286	Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. <i>Blood</i> , 2022, 140, 491-503.	0.6	32
287	The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. <i>Neuro-Oncology</i> , 2022, 24, 1408-1422.	0.6	27
288	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. <i>Journal of Clinical Medicine</i> , 2022, 11, 2513.	1.0	15
289	CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. <i>Cancers</i> , 2022, 14, 2154.	1.7	1
290	Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 737-749.	0.6	9
291	Update on primary plasma cell leukemia. <i>Blood Research</i> , 2022, 57, S62-S66.	0.5	7



#	ARTICLE	IF	CITATIONS
292	Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 473-482.	0.6	20
293	Demographic differences among patients treated with chimeric antigen receptor T cell therapy in the United States. <i>Cancer Medicine</i> , 2022, 11, 4440-4448.	1.3	6
294	Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. <i>Nature Medicine</i> , 2022, 28, 1189-1198.	15.2	190
295	Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. <i>Cytotherapy</i> , 2022, 24, 940-953.	0.3	5
296	Chimeric Antigen Receptor Based Cellular Therapy for Treatment Of T-Cell Malignancies. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
297	Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma. <i>PLoS ONE</i> , 2022, 17, e0267979.	1.1	6
298	Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. <i>American Journal of Hematology</i> , 2022, 97, 1086-1107.	2.0	208
299	CAR-T Cell Performance: How to Improve Their Persistence?. <i>Frontiers in Immunology</i> , 2022, 13, 878209.	2.2	42
300	Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma—Challenges and Potential Solutions. <i>JAMA Oncology</i> , 2022, 8, 823.	3.4	6
301	Novel immunotherapies in multiple myeloma. <i>International Journal of Hematology</i> , 2022, 115, 799-810.	0.7	3
302	Risk factors of tumor lysis syndrome in relapsed/refractory multiple myeloma patients undergoing BCMA CAR-T cell therapy. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 144-150.	0.1	2
303	How I approach smoldering multiple myeloma. <i>Blood</i> , 2022, 140, 828-838.	0.6	10
304	Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma. <i>Blood</i> , 2022, 140, 594-607.	0.6	14
305	Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239.	1.3	119
306	Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Future Oncology</i> , 2022, 18, 2415-2431.	1.1	2
307	Enabling CAR-T cells for solid tumors: Rage against the suppressive tumor microenvironment. <i>International Review of Cell and Molecular Biology</i> , 2022, , 123-147.	1.6	8
308	CAR-T cell therapy for multiple myeloma: current practice and future perspectives. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 144-150.	0.1	2
309	Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. <i>Cytotherapy</i> , 2022, 24, 962-973.	0.3	6

#	ARTICLE	IF	CITATIONS
310	Idecabtagene vicleucel versus ciltacabtagene autoleucel: a Sophieâ€™s choice for patients with relapsed refractory multiple myeloma. <i>Expert Review of Hematology</i> , 2022, 15, 473-475.	1.0	10
311	Moving Toward a Cure for Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 1-12.	1.8	2
312	Systematic Review of Available CAR-T Cell Trials around the World. <i>Cancers</i> , 2022, 14, 2667.	1.7	31
313	CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies. <i>Cells</i> , 2022, 11, 1804.	1.8	1
314	Longitudinal Collection of Patient-Reported Outcomes and Activity Data during CAR-T Therapy: Feasibility, Acceptability, and Data Visualization. <i>Cancers</i> , 2022, 14, 2742.	1.7	6
315	BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events. <i>Expert Review of Hematology</i> , 2022, 15, 503-517.	1.0	1
316	An update on novel multiple myeloma targets. <i>Expert Review of Hematology</i> , 2022, 15, 519-537.	1.0	1
317	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
319	Barriers and solutions to improve access for chimeric antigen receptor therapies. <i>Immunotherapy</i> , 2022, 14, 741-753.	1.0	3
320	Updates in the Treatment of Multiple Myeloma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 584-588.	2.3	0
321	Ciltacabtagene Autoleucel, an Antiâ€™B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. <i>Journal of Clinical Oncology</i> , 2023, 41, 1265-1274.	0.8	160
322	Teclistamab in Relapsed or Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 495-505.	13.9	291
323	Pathogenesis and treatment of multiple myeloma. <i>MedComm</i> , 2022, 3, .	3.1	8
324	CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	10
325	The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma. <i>Translational Oncology</i> , 2022, 22, 101448.	1.7	5
326	Therapeutics to harness the immune microenvironment in multiple myeloma. <i>Cancer Drug Resistance (Alhambra, Calif )</i> , 2022, 5, 647-61.	0.9	6
327	Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	22
328	CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	55

#	ARTICLE	IF	CITATIONS
329	Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland. , 2022, 152, .		5
331	Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy. Current Cardiology Reviews, 2022, 18, .	0.6	1
332	Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) Tâ€cellular therapy development. Clinical and Translational Science, 2022, 15, 2057-2074.	1.5	9
333	Melflufen for the treatment of multiple myeloma. Expert Review of Clinical Pharmacology, 2022, 15, 371-382.	1.3	3
334	The Past, Present, and Future of Non-Viral CAR T Cells. Frontiers in Immunology, 0, 13, .	2.2	39
335	Review: Sustainable Clinical Development of CAR-T Cells â€ Switching From Viral Transduction Towards CRISPR-Cas Gene Editing. Frontiers in Immunology, 0, 13, .	2.2	20
336	Quantitative Clinical Pharmacology of CAR Tâ€Cell Therapy. Clinical Pharmacology and Therapeutics, 2022, 112, 11-15.	2.3	2
337	WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma. , 2022, 10, e004409.		9
338	Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. Pharmaceutical Medicine, 2022, 36, 163-171.	1.0	19
339	Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?. Hemato, 2022, 3, 385-413.	0.2	2
340	Synthetic Immunotherapy: Programming Immune Cells with Novel and Sophisticated Logic Capabilities. Transplantation and Cellular Therapy, 2022, 28, 560-571.	0.6	4
341	T cells isolated from G-CSF-treated multiple myeloma patients are suitable for the generation of BCMA-directed CAR-T cells. Molecular Therapy - Methods and Clinical Development, 2022, 26, 207-223.	1.8	3
342	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	33
343	Multiple Myeloma: Possible Cure from the Sea. Cancers, 2022, 14, 2965.	1.7	4
344	Fertility and CAR T-cells: Current practice and future directions. Transplantation and Cellular Therapy, 2022, 28, 605.e1-605.e8.	0.6	5
345	Impact of belantamab mafodotinâ€induced ocular toxicity on outcomes of patients with advanced multiple myeloma. British Journal of Haematology, 2022, 199, 95-99.	1.2	14
346	Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Annals of Oncology, 2022, 33, 916-928.	0.6	30
347	A Bridge To CAR. Transplantation and Cellular Therapy, 2022, 28, 282-283.	0.6	1

#	ARTICLE	IF	CITATIONS
348	Bispecific Tâ€cell engagers for treatment of multiple myeloma. American Journal of Hematology, 2023, 98, .	2.0	13
349	Engineering Next-Generation CAR-T Cells: Overcoming Tumor Hypoxia and Metabolism. Annual Review of Chemical and Biomolecular Engineering, 2022, 13, 193-216.	3.3	15
350	Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. Frontiers in Oncology, 0, 12, .	1.3	2
351	Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display. Frontiers in Immunology, 0, 13, .	2.2	2
352	Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion, 0, , .	0.8	0
353	Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future. Frontiers in Immunology, 0, 13, .	2.2	69
354	T-cell Immunotherapy and Cardiovascular Disease. Heart Failure Clinics, 2022, 18, 443-454.	1.0	2
355	InÂvivo generation of CAR T cells in the presence of human myeloid cells. Molecular Therapy - Methods and Clinical Development, 2022, 26, 144-156.	1.8	8
356	Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR TÂcells inÂvitro and inÂvivo. Molecular Therapy - Oncolytics, 2022, 26, 120-134.	2.0	4
357	Toxicity management strategies for next-generation novel therapeutics in multiple myeloma. Therapeutic Advances in Hematology, 2022, 13, 204062072211006.	1.1	4
358	Chimeric antigen receptor T cells and management of toxicities: implications of biomarkers. , 2022, , 245-281.		0
359	Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma: The Anti-BCMA Therapy-refractory Patient. Touch Reviews in Oncology & Haematology, 2022, 18, 59.	0.1	1
360	Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211071.	1.4	6
361	Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. Touch Reviews in Oncology & Haematology, 2022, 18, 53.	0.1	0
362	Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer Journal, 2022, 12, .	2.8	16
363	Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma. Annals of Hematology, 2022, 101, 1755-1767.	0.8	2
364	Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies. Cancers, 2022, 14, 3230.	1.7	23
365	Expanding anti-CD38 immunotherapy for lymphoid malignancies. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	15

#	ARTICLE	IF	CITATIONS
366	Real-World Experience and Optimization of Outpatient Chimeric Antigen Receptor T Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, 583-585.	0.6	6
367	What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. Targeted Oncology, 2022, 17, 383-405.	1.7	7
368	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
369	Targeting the Microenvironment for Treating Multiple Myeloma. International Journal of Molecular Sciences, 2022, 23, 7627.	1.8	9
370	Socioeconomic and Racial Disparity in Chimeric antigen receptor T cell (CART)Therapy Access. Transplantation and Cellular Therapy, 2022, 28, 345-346.	0.6	2
371	Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan. Japanese Journal of Clinical Oncology, 0, , .	0.6	1
372	A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. Journal of Cancer Research and Clinical Oncology, 2023, 149, 2757-2769.	1.2	4
373	On the continuous (R)evolution of antibody-based and CAR T cell therapies in multiple myeloma: an early 2022 glance into the future. Expert Opinion on Pharmacotherapy, 2022, 23, 1425-1444.	0.9	1
374	Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. , 2022, 10, e004222.		14
375	The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells. Transplantation and Cellular Therapy, 2022, 28, 650-656.	0.6	6
376	Current landscape of gene editing technology in biomedicine: Applications, advantages, challenges, and perspectives. MedComm, 2022, 3, .	3.1	2
377	Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy. Biomedicines, 2022, 10, 1638.	1.4	5
378	Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation, 2022, 57, 1477-1488.	1.3	28
379	Cellular kinetics: A clinical and computational review of CAR-T cell pharmacology. Advanced Drug Delivery Reviews, 2022, 188, 114421.	6.6	18
380	Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. OncoTargets and Therapy, 0, Volume 15, 799-813.	1.0	3
381	Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing. Journal of the American Chemical Society, 2022, 144, 13851-13864.	6.6	20
382	Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer, 2022, 22, 557-575.	12.8	208
383	Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective. Transplantation and Cellular Therapy, 2022, 28, 727-736.	0.6	5

#	ARTICLE	IF	CITATIONS
385	Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	17
386	Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	47
387	Patient experience before and after treatment with idecabtagene vicleucel (ide-cel, bb2121): qualitative analysis of patient interviews in the KarMMa trial. <i>Leukemia Research</i> , 2022, 120, 106921.	0.4	4
388	Minimal Residual Disease in Multiple Myeloma—Current Approaches and Future Clinical Implications. <i>Hemato</i> , 2022, 3, 454-465.	0.2	1
389	Identification of CD8+ T-cell epitope from multiple myeloma-specific antigen AKAP4. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
390	Treatment horizon in multiple myeloma. <i>European Journal of Haematology</i> , 2022, 109, 425-440.	1.1	6
391	Natural killer cells: the next wave in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
392	A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2022, 13, 31-43.	0.2	0
393	Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. <i>Current Opinion in Oncology</i> , 2022, 34, 524-530.	1.1	2
394	Novel Quadruplets and the Age of Immunotherapies in the Treatment of Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 0, , .	3.4	1
395	Severe infections in recipients of cancer immunotherapy: what intensivists need to know. <i>Current Opinion in Critical Care</i> , 2022, 28, 540-550.	1.6	5
396	Multiple Myeloma Therapy: Emerging Trends and Challenges. <i>Cancers</i> , 2022, 14, 4082.	1.7	19
397	Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 723-726.	0.6	14
399	CAR T cells in multiple myeloma: Where we stand and where we might be going. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	0
400	Recent Advances and Challenges in Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 3972.	1.7	26
401	T Recent advances of FDA-approved CAR-T therapies in multiple myeloma. , 0, 8, 380-389.		0
402	Chimeric Antigen Receptor-T Cell Therapy. <i>Korean Journal of Medicine</i> , 2022, 97, 229-237.	0.1	0
403	When an embarrassment of riches isn't enough. <i>Nature Reviews Clinical Oncology</i> , 0, , .	12.5	0

#	ARTICLE	IF	CITATIONS
404	Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. <i>Med</i> , 2022, 3, 538-564.	2.2	11
405	Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
406	Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. <i>Blood Advances</i> , 2023, 7, 1056-1064.	2.5	13
407	CAR T Cells Contend with Myeloma in the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2022, 3, 478-480.	2.6	2
408	Geographic and Racial Disparities in Access to Chimeric Antigen Receptor T Cells and Bispecific Antibodies Trials for Multiple Myeloma. <i>JAMA Network Open</i> , 2022, 5, e2228877.	2.8	21
409	Secretory co-factors in next-generation cellular therapies for cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
410	Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment. <i>Biomolecules</i> , 2022, 12, 1146.	1.8	3
411	Overcoming tumor resistance mechanisms in CAR-NK cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	22
412	β-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	11
414	High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. <i>Nature Biotechnology</i> , 2023, 41, 521-531.	9.4	77
415	Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 912-919.	0.2	5
416	Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CART therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
417	Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. <i>Blood Advances</i> , 2023, 7, 644-648.	2.5	8
418	Bispecific Antibodies for the Treatment of Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 286-297.	1.2	4
419	T-Cell Engagers – Modern Immune-Based Therapies for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 558-561.	13.9	7
420	Road testing new CAR design strategies in multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
421	Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. <i>Blood Advances</i> , 2022, 6, 6109-6119.	2.5	23
422	Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	20

#	ARTICLE	IF	CITATIONS
423	Epigenetic engineering for optimal CAR-T cell therapy. <i>Cancer Science</i> , 0, , .	1.7	4
424	Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. <i>Blood Cancer Discovery</i> , 2022, 3, 490-501.	2.6	38
425	Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	3
426	Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. <i>Blood</i> , 2023, 141, 219-230.	0.6	52
427	CAR-T cells—Real-time experience applying CAR-T cells—What we have learned so far. <i>Memo - Magazine of European Medical Oncology</i> , 2022, 15, 173-175.	0.3	0
428	Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
429	Leaving Lytic Lesions—Is There New Role for Radiation in Multiple Myeloma in the CAR T Era?. <i>Practical Radiation Oncology</i> , 2022, 12, 367-369.	1.1	1
430	EXABS-170-MM CART Cell +/- Maintenance Will Replace Auto-SCT in NDMM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S77.	0.2	0
431	EXABS-169-MM Debate: Auto + Maintenance Should Remain SOC. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S75-S76.	0.2	0
432	EXABS-123-MM Additional Agents for RRMM - How Do/Will They Fit. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, S24-S26.	0.2	0
433	Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. <i>Lancet Haematology</i> , 2022, 9, e786-e795.	2.2	18
434	Applying a clinical lens to animal models of CAR-T cell therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 27, 17-31.	1.8	18
435	Roadmap for New Practitioners to Navigate the Multiple Myeloma Landscape. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
436	Multiple Myeloma with Hyperammonemia Treated with Novel Agents: A Case Series of Three Patients. <i>Internal Medicine</i> , 2022, , .	0.3	1
437	Relapse Mechanism and Treatment Strategy After Chimeric Antigen Receptor T-Cell Therapy in Treating B-Cell Hematological Malignancies. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211184.	0.8	2
438	A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen – CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3576-3586.	0.8	47
439	CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 0, Volume 12, 119-136.	1.2	15
441	T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments. <i>Cancers</i> , 2022, 14, 4249.	1.7	2



#	ARTICLE	IF	CITATIONS
442	Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations. <i>BMJ</i> , The, 0, , e068956.	3.0	4
443	Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 4192.	1.7	6
444	Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. <i>Nature</i> , 2022, 609, 369-374.	13.7	113
445	Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. <i>Clinical Cancer Research</i> , 2022, 28, 5156-5166.	3.2	10
446	All-trans retinoic acid works synergistically with the $\beta$ -secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells. <i>Haematologica</i> , 2023, 108, 568-580.	1.7	7
447	Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma. <i>Cancer Medicine</i> , 2023, 12, 3999-4009.	1.3	3
448	The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucl and Idecabtagene Vicleucl for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. <i>BioDrugs</i> , 2022, 36, 773-780.	2.2	6
449	GPRC5D-Targeted CAR T Cells for Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 1196-1206.	13.9	114
450	Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1455-1476.	2.0	8
451	CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
452	Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 22-27.	0.2	2
453	Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	21
454	Steps towards a Multiple Myeloma Cure?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1451.	1.1	3
455	Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting. <i>Experimental Hematology and Oncology</i> , 2022, 11, .	2.0	8
456	Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 4769.	1.7	3
457	Ciltacabtagene autoleucl: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
458	Mechanism of immunomodulatory drug resistance and novel therapeutic strategies in multiple myeloma. <i>Hematology</i> , 2022, 27, 1110-1121.	0.7	3
459	Paving the road to make chimeric antigen receptor-cell therapy effective against solid tumors. <i>Cancer Science</i> , 2022, 113, 4020-4029.	1.7	2

#	ARTICLE	IF	CITATIONS
460	Updates on Multiple Myeloma: What's New in Risk Stratification, Treatment, and Prognosis. , 0, , .		0
461	Clinical implications of measurable residual disease assessment in multiple myeloma in the era of quadruplet therapy. <i>Leukemia and Lymphoma</i> , 2022, 63, 3288-3298.	0.6	3
462	Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12366.	1.2	17
463	Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. , 2022, 10, e005145.		9
464	The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study. <i>Annals of Translational Medicine</i> , 2022, 10, 975-975.	0.7	2
465	Co-Stimulatory Receptor Signaling in CAR-T Cells. <i>Biomolecules</i> , 2022, 12, 1303.	1.8	11
466	CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil. <i>Hematology, Transfusion and Cell Therapy</i> , 2023, 45, 266-274.	0.1	3
467	Roadmap for new practitioners to navigate the multiple myeloma landscape. <i>Heliyon</i> , 2022, 8, e10586.	1.4	0
468	Cardiovascular disease and chimeric antigen receptor cellular therapy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
469	CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome. <i>Science Advances</i> , 2022, 8, .	4.7	19
470	Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report. , 2022, 10, e005403.		7
471	High antigen density of BCMA: friend or foe to CAR T cells?. , 2022, 10, e005822.		1
472	Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: <sc>CARTITUDE</sc> (phase 2) Japanese cohort. <i>Cancer Science</i> , 2022, 113, 4267-4276.	1.7	6
473	Iberdomide with dexamethasone: a new backbone for myeloma treatment?. <i>Lancet Haematology</i> , the, 2022, 9, e799-e801.	2.2	1
474	The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. <i>American Journal of Hematology</i> , 2023, 98, .	2.0	10
475	Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study. <i>British Journal of Haematology</i> , 2023, 200, 45-53.	1.2	16
476	Trial designs and endpoints for immune therapies in multiple myeloma. <i>American Journal of Hematology</i> , 0, , .	2.0	1
477	Subsequent anti-myeloma therapy after maturation antigen (<sc>BCMA</sc>) chimeric antigen receptor (<sc>CAR</sc>) cell (<sc>HDS269B</sc>) treatment in patients with relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3

#	ARTICLE	IF	CITATIONS
478	BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Cancer Letters</i> , 2023, 553, 215949.	3.2	11
479	Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. <i>Haematologica</i> , 2023, 108, 1827-1839.	1.7	7
480	Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, e14-e18.	0.2	1
481	Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective. <i>Cancer Letters</i> , 2022, 550, 215920.	3.2	11
482	17. Molecular Pathogenesis and Therapeutic Advances in Multiple Myeloma. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 2028-2036.	0.0	0
483	Two to Tango: CD3/BCMA Bispecific Antibodies in Multiple Myeloma. , 2022, 19, .		0
484	Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382211329.	0.8	2
485	The journey of CAR-T therapy in hematological malignancies. <i>Molecular Cancer</i> , 2022, 21, .	7.9	45
486	The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2023, 64, 261-272.	0.6	2
487	NK cell therapy in relapsed refractory multiple myeloma. <i>Clinical Immunology</i> , 2023, 246, 109168.	1.4	2
488	Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. <i>Bone Marrow Transplantation</i> , 2023, 58, 80-86.	1.3	1
489	Bispecific antibodies in multiple myeloma treatment: A journey in progress. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	17
490	Whole-process management of complications during CART-T therapy. , 2022, 1, .		0
491	Structured expert elicitation to inform long-term survival extrapolations using alternative parametric distributions: a case study of CAR T therapy for relapsed/ refractory multiple myeloma. <i>BMC Medical Research Methodology</i> , 2022, 22, .	1.4	3
492	Tumor buster - where will the CAR-T cell therapy "missile" go?. <i>Molecular Cancer</i> , 2022, 21, .	7.9	23
493	Anti-Apoptotic c-FLIP Reduces the Anti-Tumour Activity of Chimeric Antigen Receptor T Cells. <i>Cancers</i> , 2022, 14, 4854.	1.7	1
494	Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	3
495	Genome-edited allogeneic donor "universal" chimeric antigen receptor T cells. <i>Blood</i> , 2023, 141, 835-845.	0.6	11

#	ARTICLE	IF	CITATIONS
496	BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. <i>Haematologica</i> , 2023, 108, 958-968.	1.7	11
497	Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
498	Emerging frontiers in immuno- and gene therapy for cancer. <i>Cytotherapy</i> , 2023, 25, 20-32.	0.3	3
499	The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
500	Multiple immunoglobulin isotype switch after bispecific <scp>CARâ€‹</scp> cell therapy in multiple myelomaâ€”A case report. <i>British Journal of Haematology</i> , 0, , .	1.2	1
501	Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology. <i>OncolImmunology</i> , 2022, 11, .	2.1	1
502	Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucl in CARTITUDE-1 versus idecabtagene vicleucl in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. <i>Current Medical Research and Opinion</i> , 2023, 39, 81-89.	0.9	6
503	Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	2
504	Chimeric Antigen Receptor Immunotherapy for Solid Tumors: Choosing the Right Ingredients for the Perfect Recipe. <i>Cancers</i> , 2022, 14, 5351.	1.7	1
505	Immunotherapy for the treatment of multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
506	Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
508	Phase II, Open-Label Study of Ciltacabtagene Autoleucl, an Antiâ€”B-Cell Maturation Antigen Chimeric Antigen Receptorâ€”T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1). <i>Journal of Clinical Oncology</i> , 2023, 41, 1275-1284.	0.8	15
509	Advances in immunotherapy for glioblastoma multiforme. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
510	Migratory Engineering of T Cells for Cancer Therapy. <i>Vaccines</i> , 2022, 10, 1845.	2.1	8
511	Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. , 2022, 10, e005091.		11
512	Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13332.	1.8	10
515	Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. <i>Blood</i> , 2023, 141, 756-765.	0.6	27
516	Immunotherapy approaches for hematological cancers. <i>IScience</i> , 2022, 25, 105326.	1.9	9

#	ARTICLE	IF	CITATIONS
517	Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US. <i>Clinical Drug Investigation</i> , 0, , .	1.1	0
518	Toxicities following CAR-T therapy for hematological malignancies. <i>Cancer Treatment Reviews</i> , 2022, 111, 102479.	3.4	13
519	Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice. <i>Biomaterials</i> , 2022, 291, 121872.	5.7	12
520	Novel and Experimental Clone-Directed Therapies. , 2022, , 355-376.		0
521	New drug approvals for 2021: Synthesis and clinical applications. <i>European Journal of Medicinal Chemistry</i> , 2023, 245, 114898.	2.6	15
522	A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy. <i>Blood Advances</i> , 2023, 7, 2479-2493.	2.5	4
523	Antibody Drug Conjugates in Multiple Myeloma. <i>Cancer Journal (Sudbury, Mass )</i> , 2022, 28, 488-495.	1.0	1
524	Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
525	The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. <i>Expert Review of Proteomics</i> , 2022, 19, 235-246.	1.3	3
527	Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients. <i>Current Oncology</i> , 2022, 29, 8501-8512.	0.9	0
528	Changing the Tune for CAR T-Cell Therapy: A Music City Experience in Remote Patient Monitoring. <i>Oncology Issues</i> , 2022, 37, 20-24.	0.0	1
529	Engineered T cell therapy for viral and non-viral epithelial cancers. <i>Cancer Cell</i> , 2023, 41, 58-69.	7.7	13
530	A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy. <i>International Immunopharmacology</i> , 2023, 114, 109592.	1.7	1
532	The future of engineered immune cell therapies. <i>Science</i> , 2022, 378, 853-858.	6.0	38
533	How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells. <i>Journal of Clinical Oncology</i> , 2023, 41, 1342-1349.	0.8	4
534	Positive regulators of T cell proliferation as biomarkers for predicting prognosis and characterizing the immune landscape in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
535	Innovation in BCMA CAR-T therapy: Building beyond the Model T. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
536	Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. <i>Nature Communications</i> , 2022, 13, .	5.8	18

#	ARTICLE	IF	CITATIONS
537	Immunotherapy approaches for rare pediatric solid tumors: advances and future directions. <i>Current Opinion in Pediatrics</i> , 2023, 35, 63-74.	1.0	0
538	Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment. <i>Current Oncology</i> , 2022, 29, 8975-9005.	0.9	9
539	Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. <i>Blood Cancer Discovery</i> , 2023, 4, 118-133.	2.6	22
540	Multiplexed engineering and precision gene editing in cellular immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
541	EEG-based grading of immune effector cell-associated neurotoxicity syndrome. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
542	Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. , 2022, 10, e005459.		4
543	Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	2
544	Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?. <i>Cancers</i> , 2022, 14, 6026.	1.7	4
545	Synthetic cytokine circuits that drive T cells into immune-excluded tumors. <i>Science</i> , 2022, 378, .	6.0	56
546	Fitness and frailty in myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 337-348.	0.9	4
547	Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15879.	1.8	1
548	Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition. <i>International Immunopharmacology</i> , 2022, 113, 109442.	1.7	2
549	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
550	Engineering chimeric antigen receptor T cells for solid tumour therapy. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	13
551	Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1006-1010.	0.5	2
552	Chimeric Antigen Receptor T Cells: Toxicity and Management Considerations. <i>AACN Advanced Critical Care</i> , 2022, 33, 301-307.	0.6	1
553	Talquetamab, a T-Cell Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2022, 387, 2232-2244.	13.9	134
554	Dose response correlation for CAR-T cells: a systematic review of clinical studies. , 2022, 10, e005678.		15

#	ARTICLE	IF	CITATIONS
555	Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. <i>Bone Marrow Transplantation</i> , 2023, 58, 443-445.	1.3	9
556	Single cell multi-omic reference atlases of non-human primate immune tissues reveals CD102 as a biomarker for long-lived plasma cells. <i>Communications Biology</i> , 2022, 5, .	2.0	4
557	Chimeric antigen receptor T-cell therapy for multiple myeloma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
558	Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2709-2734.	1.2	6
559	Coated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro. <i>Immunologic Research</i> , 2023, 71, 276-282.	1.3	4
560	The emerging therapeutic landscape of relapsed/refractory multiple myeloma. <i>Annals of Hematology</i> , 2023, 102, 1-11.	0.8	12
562	Phase I CAR-T Clinical Trials Review. <i>Anticancer Research</i> , 2022, 42, 5673-5684.	0.5	0
563	Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities. <i>JCO Oncology Practice</i> , 2023, 19, e407-e416.	1.4	2
564	Acute Kidney Injury in Cancer Immunotherapy Recipients. <i>Cells</i> , 2022, 11, 3991.	1.8	4
565	Targeting TGF- $\beta$ signaling in the multiple myeloma microenvironment: Steering CARs and T cells in the right direction. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	5
566	Cellular therapy for multiple myeloma: what's now and what's next. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 180-189.	0.9	10
567	Progressive multifocal leukoencephalopathy in multiple myeloma. <i>European Journal of Haematology</i> , 0, , .	1.1	1
568	Cardiotoxicity of T-Cell Antineoplastic Therapies. <i>JACC: CardioOncology</i> , 2022, 4, 616-623.	1.7	10
570	Evaluating the Patient with Neurotoxicity after Chimeric Antigen Receptor T-cell Therapy. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1845-1860.	1.3	2
571	Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
572	Disease Monitoring In Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, , .	0.2	0
573	Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 275-285.	157.7	24
575	The impact of current therapeutic options on the health-related quality of life of patients with relapse/refractory multiple myeloma: a systematic review of clinical studies. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	1

#	ARTICLE	IF	CITATIONS
576	Real-world assessment of treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma in an Italian haematological tertiary care centre. <i>British Journal of Haematology</i> , 2023, 201, 432-442.	1.2	4
577	CAR-T cell therapy in myeloma: hopes and hurdles. <i>Blood Science</i> , 0, Publish Ahead of Print, .	0.4	1
578	Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 260.e1-260.e6.	0.6	3
579	A phase 2 clinical trial of combined BRAF/MEK inhibition for <i>BRAF</i> -mutated multiple myeloma. <i>Blood</i> , 2023, 141, 1685-1690.	0.6	11
580	Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium. <i>Journal of Clinical Oncology</i> , 2023, 41, 2087-2097.	0.8	67
581	Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus. <i>Viruses</i> , 2023, 15, 202.	1.5	5
582	GPRC5D: The Next Frontier for Immunotherapy in Multiple Myeloma. , 2023, 20, .		1
583	Molecular and therapeutic effect of CRISPR in treating cancer. , 2023, 40, .		2
584	CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses. , 2023, 11, e005878.		11
585	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. <i>Cancer Cell</i> , 2023, 41, 210-225.e5.	7.7	32
586	Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments. <i>Hematology Reports</i> , 2023, 15, 57-65.	0.3	1
587	Chimeric Antigen Receptor T-Cell Therapy for Patients With Multiple Myeloma—A Call for Equal Opportunity. <i>JAMA Oncology</i> , 2023, 9, 297.	3.4	1
588	Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
589	Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. <i>Current Research in Translational Medicine</i> , 2023, 71, 103378.	1.2	2
590	CD137 (4-1BB)-Based Cancer Immunotherapy on Its 25th Anniversary. <i>Cancer Discovery</i> , 2023, 13, 552-569.	7.7	19
591	Real-world treatment patterns and outcomes of triple-class treated patients with multiple myeloma in the United States. <i>Expert Review of Hematology</i> , 0, , 1-10.	1.0	0
592	Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. <i>International Journal of Molecular Sciences</i> , 2023, 24, 645.	1.8	4
593	How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> , 2023, 15, 155.	1.7	3



#	ARTICLE	IF	CITATIONS
594	Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma. <i>Cancer Control</i> , 2023, 30, 107327482211429.	0.7	4
595	Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 971-985.	3.2	6
596	Impact of Precision Medicine in Oncology. <i>Cancer Journal (Sudbury, Mass )</i> , 2023, 29, 15-19.	1.0	1
597	Expertsâ€™ consensus on the definition and management of high risk multiple myeloma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
598	Chimeric antigen receptor-modified cells for the treatment of solid tumors: First steps in a thousand-mile march. , 2023, , 97-131.		0
599	Cellular and Vaccine-Based Immunotherapy for Hematologic Malignancies. , 2023, , .		0
601	Th17.1 cell driven sarcoidosis-like inflammation after anti-BCMA CAR T cells in multiple myeloma. <i>Leukemia</i> , 2023, 37, 650-658.	3.3	14
602	CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. <i>Molecular Cancer</i> , 2023, 22, .	7.9	65
603	Drug class refractoriness, not number of prior lines of therapy, properly classify patients with relapsed and refractory multiple myeloma. <i>British Journal of Haematology</i> , 2023, 200, 824-827.	1.2	5
604	Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. <i>Cancers</i> , 2023, 15, 852.	1.7	6
605	Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. <i>International Journal of Hematology</i> , 2023, 117, 729-737.	0.7	1
606	Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. <i>Nature Medicine</i> , 2023, 29, 422-429.	15.2	56
607	Off-the-shelf CAR T cells for multiple myeloma. <i>Nature Medicine</i> , 2023, 29, 303-304.	15.2	2
608	Reply to E.R.S. Cliff et al. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	0
610	Immunotherapy for Multiple Myeloma. , 2023, , 1-22.		0
611	Combining radiotherapy and NK cell-based therapies: The time has come. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1
612	GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. <i>Lancet Haematology</i> ,the, 2023, 10, e107-e116.	2.2	36
613	Characterizing the exposureâ€“response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 1687-1697.	1.3	3

#	ARTICLE	IF	CITATIONS
614	Early Stage Professionals Committee Proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting. <i>Cytotherapy</i> , 2023, , .	0.3	0
615	Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data. <i>Pharmacological Research</i> , 2023, 190, 106742.	3.1	4
616	Highlights into historical and current immune interventions for cancer. <i>International Immunopharmacology</i> , 2023, 117, 109882.	1.7	2
617	Metabolic challenges and interventions in CAR T cell therapy. <i>Science Immunology</i> , 2023, 8, .	5.6	13
618	T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma. <i>Cytotherapy</i> , 2023, 25, 490-501.	0.3	0
619	Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies. <i>European Journal of Cancer</i> , 2023, 186, 27-37.	1.3	1
620	Non-viral chimeric antigen receptor (CAR) T cells going viral. <i>Immuno-Oncology Technology</i> , 2023, 18, 100375.	0.2	8
621	CARTIFAN-1: Concerning fatal adverse events with global use of chimeric antigen receptorâ€T-cell therapy in multiple myeloma. <i>European Journal of Cancer</i> , 2023, 182, 1-2.	1.3	3
622	Biology and status of chimeric antigen receptor-engineered T cell therapy. , 2023, , 149-165.		0
623	Chimeric Antigen Receptor T-cell Therapy in Hematologic Malignancies and Patient-reported Outcomes: A Scoping Review. <i>HemaSphere</i> , 2022, 6, e802.	1.2	7
625	Case report: Cryoablation as a novel bridging strategy prior to CAR-T cell therapy for B cell malignancies with bulky disease. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
626	Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France. <i>Journal of Medical Economics</i> , 2023, 26, 243-253.	1.0	2
627	Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
628	Haploidentical Î³Î³ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2023, 46, 56-58.	1.2	3
629	HÃmatologische Neoplasien und solide Tumore. , 2022, , 85-151.		0
630	SOHO State-of-the-Art Updates and Next Questions   BCMA-Directed CAR T-Cells: Early Results and Future Directions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2023, 23, 310-321.	0.2	3
631	Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3136.	1.8	5
632	The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma. <i>BMC Cancer</i> , 2023, 23, .	1.1	1

#	ARTICLE	IF	CITATIONS
633	Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome. <i>Lancet Haematology</i> , 2023, 10, e161-e162.	2.2	1
634	CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy. <i>Cancers</i> , 2023, 15, 1052.	1.7	4
635	IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM. , 2023, 11, e006239.		10
636	CAR-T Cell Therapy: the Efficacy and Toxicity Balance. <i>Current Hematologic Malignancy Reports</i> , 2023, 18, 9-18.	1.2	15
637	Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2023, 388, 1002-1014.	13.9	123
638	A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	4
639	Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 722-726.	0.5	4
640	Pomalidomide combinations are a safe and effective option after daratumumab failure. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
641	Optimizing the manufacturing and antitumour response of CARÂT therapy. , 2023, 1, 271-285.		14
642	Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. <i>Current Oncology</i> , 2023, 30, 2322-2347.	0.9	10
643	Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. <i>Haematologica</i> , 2023, 108, 2011-2028.	1.7	3
644	Measurable residual disease after CAR T-cell therapy. <i>Seminars in Hematology</i> , 2023, 60, 34-41.	1.8	0
645	CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	15
646	A Novel Cell-based Luciferase Reporter Platform for the Development and Characterization of T-Cell Redirecting Therapies and Vaccine Development. <i>Journal of Immunotherapy</i> , 2023, 46, 96-106.	1.2	1
647	Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	4
648	CAR immune cells: design principles, resistance and the next generation. <i>Nature</i> , 2023, 614, 635-648.	13.7	96
649	Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients. <i>Haematologica</i> , 2023, 108, 2799-2802.	1.7	4
650	Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A realâ€world multicentre <sc>UK</sc> retrospective analysis. <i>British Journal of Haematology</i> , 0, , .	1.2	1

#	ARTICLE	IF	CITATIONS
651	Deconvolution of clinical variance in CAR-T cell pharmacology and response. <i>Nature Biotechnology</i> , 2023, 41, 1606-1617.	9.4	9
652	Challenges and optimal strategies of CAR T therapy for hematological malignancies. <i>Chinese Medical Journal</i> , 2023, 136, 269-279.	0.9	2
654	An Overview of Cytokine Release Syndrome and Other Side Effects of CAR-T Cell Therapy. <i>Praxis</i> , 2023, 112, 189-193.	0.2	2
655	Infectious complications of chimeric antigen receptor (CAR) T-cell therapies. <i>Seminars in Hematology</i> , 2023, 60, 52-58.	1.8	2
656	Anti- $\alpha$ -G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase 1 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 2583-2593.	0.8	17
657	CAR-T cell treatment of high-risk multiple myeloma – will there be a cure?. <i>Haematologica</i> , 0, , .	1.7	0
658	Metabolic reprogramming via an engineered PGC-1 $\beta$ improves human chimeric antigen receptor T-cell therapy against solid tumors. , 2023, 11, e006522.		8
659	Combined disruption of T cell inflammatory regulators Regnase-1 and Roquin-1 enhances antitumor activity of engineered human T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	19
660	The BAFF-APRIL System in Cancer. <i>Cancers</i> , 2023, 15, 1791.	1.7	8
661	Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. <i>Nature Medicine</i> , 2023, 29, 632-645.	15.2	17
662	Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. <i>JCO Oncology Practice</i> , 0, , .	1.4	0
663	Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 350-355.	0.6	6
664	Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis. <i>Annals of Hematology</i> , 2023, 102, 1269-1270.	0.8	2
665	Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant. <i>Cancers</i> , 2023, 15, 1838.	1.7	3
666	CAR-T cell therapy in part of the B cell hematological malignancies. , 0, 36, 17-22.		0
667	Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	5
668	30 Years of Improved Survival in Non-Transplant-Eligible Newly Diagnosed Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1929.	1.7	4
669	Respiratory Viral Infections in Recipients of Cellular Therapies: A Review of Incidence, Outcomes, Treatment, and Prevention. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	2

#	ARTICLE	IF	CITATIONS
670	Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma. <i>Advances in Therapy</i> , 2023, 40, 2412-2425.	1.3	7
671	Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy. <i>International Journal of Hematology</i> , 2023, 117, 652-659.	0.7	2
672	Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 399-402.	0.6	2
674	HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	1
675	Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2023, 14, 163-171.	0.2	2
676	Evaluating process utilities for the treatment burden of chemotherapy in multiple myeloma in Japan: a time trade-off valuation study. <i>Journal of Medical Economics</i> , 2023, 26, 565-573.	1.0	0
677	Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tt trial. <i>Leukemia Research</i> , 2023, 129, 107074.	0.4	2
678	Safety of CAR-T Cell Therapy in Patients With Renal Failure/Acute Kidney Injury: Focused Review. <i>Clinical Hematology International</i> , 2023, 5, 122-129.	0.7	4
680	Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	6
681	Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma. <i>Oncology and Therapy</i> , 2023, 11, 263-275.	1.0	3
682	Management of Relapsed and Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice. <i>Cancers</i> , 2023, 15, 2160.	1.7	3
683	Preclinical discovery and initial clinical data of WVT078, a BCMA- CD3 bispecific antibody. <i>Leukemia</i> , 2023, 37, 1349-1360.	3.3	2
684	Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. <i>Cancer</i> , 0, , .	2.0	0
685	CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma. <i>Haematologica</i> , 2023, 108, 1988-1990.	1.7	1
686	Teclistamab impairs detection of BCMA CAR-T cells. <i>Blood Advances</i> , 0, , .	2.5	1
687	Current Main Topics in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 2203.	1.7	1
688	Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy. <i>Cancers</i> , 2023, 15, 2240.	1.7	3
689	Long-term outcomes following CAR T cell therapy: what we know so far. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 359-371.	12.5	119

#	ARTICLE	IF	CITATIONS
690	BTK Inhibitors and Other Targeted Therapies in Waldenström Macroglobulinemia. <i>Hemato</i> , 2023, 4, 135-157.	0.2	1
691	Apoptosis: a Janus bifrons in T-cell immunotherapy. , 2023, 11, e005967.		3
692	Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?. <i>Pharmaceuticals</i> , 2023, 16, 590.	1.7	4
693	Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients. <i>BMC Cancer</i> , 2023, 23, .	1.1	13
694	Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 418-428.	0.6	7
695	CAR-T-sejtes kezelései a hematológiai betegeknél. <i>Transfusio</i> , 2023, 55, 164-170.	0.0	0
696	A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
697	Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study. <i>Haematologica</i> , 0, , .	1.7	0
698	CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies. , 2023, 40, .		0
699	Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7626.	1.8	1
701	Management of Pathological Thoracolumbar Vertebral Fractures in Patients With Multiple Myeloma: Multidisciplinary Recommendations. <i>Global Spine Journal</i> , 2023, 13, 85S-93S.	1.2	0
703	Targeted therapy. , 2023, , 459-488.		0
704	Dawn of Hope for Improved Access to BCMA Therapy: Chimeric Antigen Receptor T Cell and Bispecific Products. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 474-475.	0.6	1
720	Chimeric Antigen Receptor Therapy in Multiple Myeloma. , 2024, , 309-329.		0
725	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0
740	CAR T-Cell Therapy and Critical Care Considerations. , 2023, , 427-435.		0
745	Editorial: T-cell directed therapies in multiple myeloma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
762	Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies. , 2024, , 125-143.		0

#	ARTICLE	IF	CITATIONS
763	Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy. , 2024, , 509-524.		0
764	Applications of synthetic biology in medical and pharmaceutical fields. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	17
765	Process and General Management of Patients Undergoing Chimeric Antigen Receptor Therapies. , 2024, , 115-122.		0
818	Laryngeal edema as a symptom of local cytokine release syndrome after BCMA-targeting CAR-T therapy for relapsed and refractory multiple myeloma. International Journal of Hematology, 0, , .	0.7	0
835	The Promise of Immunotherapeutics and Vaccines in the Treatment of Cancer. , 2023, , 1-43.		1
842	Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment. Frontiers in Oncology, 0, 13, .	1.3	0
848	Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer. Archivum Immunologiae Et Therapiae Experimentalis, 2023, 71, .	1.0	1
855	Immunotherapy in hematologic malignancies: achievements, challenges and future prospects. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	5
869	Drug delivery systems for CRISPR-based genome editors. Nature Reviews Drug Discovery, 2023, 22, 875-894.	21.5	9
874	Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy. , 2023, 40, .		3
889	BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma. Annals of Hematology, 0, , .	0.8	1
903	Widening demographic gaps in CAR-T therapy utilization for multiple myeloma in the United States. Bone Marrow Transplantation, 0, , .	1.3	0
935	Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma. Blood Cancer Journal, 2023, 13, .	2.8	3
944	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nature Reviews Drug Discovery, 2023, 22, 996-1017.	21.5	7
946	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. Experimental and Molecular Medicine, 2023, 55, 2287-2299.	3.2	7
949	Neurotoxicity of Cancer Immunotherapies Including CAR T Cell Therapy. Current Neurology and Neuroscience Reports, 0, , .	2.0	0
965	Myeloma evades T cell-engaging therapies. Nature Cancer, 2023, 4, 1534-1535.	5.7	0
968	Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment. Frontiers in Oncology, 0, 13, .	1.3	0

#	ARTICLE	IF	CITATIONS
979	Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 3931-3937.	2.0	0
1018	Addressing the disparities: the approach to the African American patient with multiple myeloma. <i>Blood Cancer Journal</i> , 2023, 13, .	2.8	1
1032	Engineered CAR-T cells: An immunotherapeutic approach for cancer treatment and beyond. <i>Advances in Protein Chemistry and Structural Biology</i> , 2024, , .	1.0	0
1073	GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. <i>Blood Cancer Journal</i> , 2024, 14, .	2.8	1
1079	Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas. <i>Blood Cancer Journal</i> , 2024, 14, .	2.8	1
1080	The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. <i>Annals of Hematology</i> , 0, , .	0.8	0
1091	HÄmatologische Neoplasien und solide Tumore. , 2023, , 99-174.		0